Baird Upgrades Celgene (CELG) to Outperform; Revlimid On The Rebound
Tweet Send to a Friend
Baird upgrades Celgene (Nasdaq: CELG) to Outperform, raises price target to $65.
Baird analyst says, "We are now buyers of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "We are now buyers of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
